Dechra acquires the rights to Malaseb®
Friday, March 4, 2022
Dechra is pleased to announce the licensing rights of the Malaseb® brand of dermatology products in the United States with Dermcare of Australia.
This partnership complements the existing Dechra dermatology by offering a well-known and trusted brand.
Mike Eldred, President of Dechra North America, stated, “The Malaseb line of dermatology products strengthens the popular Dechra dermatology product line by offering a brand that many veterinarians use and trust.”
Dechra’s companion animal portfolio focuses on endocrinology, dermatology, ophthalmology, anesthesia, fluid therapy, pain management, joint health support, and dental care. Our brands include Vetoryl® Capsules (trilostane), Zycortal® Suspension (desoxycorticosterone pivalate injectable suspension), Felimazole® Coated Tablets (methimazole), the Vetivex® line of parenteral fluids, and Phycox® joint health supplements. Osurnia® (florfenicol, terbinafine, betamethasone acetate) and the TrizUltra+Keto®, MiconaHex+Triz®, MalAcetic®, and oral anti-infective product lines, including Marboquin® (marbofloxacin) Tablets and Amoxicillin and Clavulanate Potassium for Oral Suspension, spotlight the dermatology offerings. And the recent addition of Mirataz® (mirtazapine transdermal ointment), Porus® One, and Redonyl® Ultra Feline to the portfolio supports the underserved feline market.
For questions or further information, please contact Mike Eldred or Doug Hubert:
Mike Eldred, President, North American Operations, Dechra Veterinary Products, Mike.Eldred@Dechra.com
Doug Hubert, Vice President, Sales and Marketing, Dechra Veterinary Products, Doug.Hubert@Dechra.com